The finding, in plain language
If you were told you have sleep apnea, or you are lying awake at 11pm because your snoring, morning headaches, or bone-deep fatigue finally pushed you to search, there is a piece of clinical news from the last two years that most people have not heard yet. In 2024, a large clinical trial called SURMOUNT-OSA tested tirzepatide — the medication sold as Zepbound and Mounjaro — in adults with moderate-to-severe obstructive sleep apnea and obesity. The results were significant enough that the FDA approved Zepbound for obstructive sleep apnea in adults with obesity in December 2024, the first drug ever approved specifically for that condition.
Before we go further: this article is educational and not medical advice; talk to your clinician about diagnosis and treatment. Sleep apnea has real health consequences and it deserves a real evaluation, not a self-diagnosis from a blog post.
Here is what the study actually showed. Researchers ran two 52-week trials with 469 total participants across both arms. According to the published SURMOUNT-OSA results in the New England Journal of Medicine, tirzepatide reduced the apnea-hypopnea index — which counts breathing interruptions per hour of sleep — by roughly 25 to 29 events on average, depending on which trial and whether patients were on CPAP at baseline. That translated to about a 62% reduction in event frequency compared with placebo. Body weight fell by roughly 18 to 20% over the same period. The FDA approval announcement laid out the indication precisely: Zepbound is approved for moderate-to-severe obstructive sleep apnea in adults with obesity, alongside a reduced-calorie diet and increased physical activity.
Why sleep apnea is missed in women 40–55
Here is the harder half of the story. If you are a woman in your forties or early fifties, and you have been quietly wondering whether something is wrong with your sleep, you are not paranoid. Sleep apnea in women is genuinely underdiagnosed, and the reasons matter for how you talk to your clinician.
The classic teaching picture of obstructive sleep apnea — loud snoring, a partner reporting witnessed pauses in breathing, dramatic daytime sleepiness — was built largely on male patients. Women often present differently. Insomnia is more common. Morning headaches, fatigue that does not resolve with sleep, low mood, and cognitive fog show up frequently. Snoring may be present but softer, or attributed to something else. As the American Academy of Sleep Medicine's OSA fact sheet summarizes, symptom presentation and diagnostic pathways for women have historically lagged the male-centered model, and women are meaningfully more likely to be misdiagnosed or diagnosed later than men with equivalent disease.
The perimenopausal transition compounds this. As estrogen and progesterone shift, upper-airway muscle tone and fat distribution change, and observational data suggest the risk of obstructive sleep apnea rises substantially during and after the menopausal transition compared with the premenopausal period. The NIH National Heart, Lung, and Blood Institute overview of sleep apnea lists menopause among the recognized risk factors. Layer that onto a symptom profile that reads like "just perimenopause," and it is easy to see why the diagnosis gets deferred for years — usually to the woman's real detriment.
If you are 40 or older, and you have any combination of unrefreshing sleep, insomnia, morning headaches, fatigue disproportionate to how long you were in bed, mood changes, or reflux at night, sleep apnea is at minimum worth ruling out. It is not the only explanation. It is one that gets skipped.
What SURMOUNT-OSA actually measured (and didn't)
Understanding what the trial measured matters, because the headline number — a 62% reduction in breathing events — has been oversimplified in a lot of coverage. SURMOUNT-OSA looked at four categories of outcomes: the apnea-hypopnea index (AHI) as the primary endpoint, body weight, patient-reported daytime sleepiness on the Epworth Sleepiness Scale, and hypoxic burden, which measures how much time patients spent with meaningfully low blood oxygen during sleep. Tirzepatide moved all of them in the direction clinicians want.
What the trial did not show is equally important. Tirzepatide did not eliminate the need for CPAP in most participants. A subset — patients whose AHI fell far enough to cross out of the disease-defining thresholds — could reasonably discuss coming off CPAP with their sleep clinician after a repeat study. But that was a subset, not the rule. Most patients in the trial who were on CPAP at baseline still had measurable obstructive sleep apnea at week 52. Their disease was less severe. It was not gone.
The honest framing, and the one your sleep clinician is most likely to use, is this: tirzepatide is a complementary treatment for obstructive sleep apnea in adults with obesity. It is not a CPAP replacement in general terms. For some patients it can meaningfully change the trajectory of the disease and, in a smaller group, the eventual need for positive-airway-pressure therapy. Any change to CPAP settings, mask time, or discontinuation should be a decision made with your sleep clinician and confirmed by a repeat sleep study — not a decision made from symptom improvement alone.
Why this matters for GLP-1 prior authorization
There is a coverage angle here that is worth naming clearly, especially if you have been fighting your insurer over GLP-1 access. A documented obstructive sleep apnea diagnosis is a recognized comorbidity that clinicians frequently cite in letters of medical necessity for GLP-1 appeals. Now that Zepbound has an FDA indication specifically for moderate-to-severe OSA in adults with obesity, appeals framed around that indication — rather than around weight loss alone — sit on firmer clinical and regulatory ground.
The practical implication: if you have been denied a GLP-1 for weight management and you have symptoms suggesting sleep apnea that were never worked up, a sleep evaluation is worth pursuing on its own health merits — and, if the evaluation confirms OSA, it changes what your clinician has to work with. Our GLP-1 prior authorization denial checklist walks through the appeal mechanics in detail, including the specific questions to ask your insurer about medical-necessity pathways based on documented comorbidities.
A separate note on context: the broader clinical picture of what GLP-1 medications now address extends well beyond weight, and we cover that in our GLP-1 benefits beyond weight loss pillar. Sleep apnea is one of the newer additions to that list, and it is arguably one of the most quality-of-life-relevant for women in perimenopause.
Tirzepatide vs compounded tirzepatide for OSA
This is where clarity matters most, because the language around brand versus compounded gets blurred in a lot of marketing. Here are the facts. SURMOUNT-OSA tested brand-name Zepbound, titrated from 5 mg up to 15 mg over the course of the trial. The FDA approval for obstructive sleep apnea in adults with obesity applies specifically to Zepbound. Compounded tirzepatide is a distinct category: it is prepared by licensed compounding pharmacies under physician supervision, and it is not FDA-approved for any indication, including sleep apnea. FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Individual results vary.
If a compounded program is the right clinical fit for you, that is a decision a licensed clinician makes with you based on your full history — not because a sleep-apnea diagnosis automatically makes any tirzepatide product appropriate. Our overview of the two categories, side by side, is in the compounded tirzepatide vs Zepbound comparison. If you are a woman navigating perimenopausal weight changes alongside sleep issues, the menopause weight loss and GLP-1 guide covers the wider clinical picture.
The point is not that one path is right and one is wrong. The point is that they are different regulatory categories, and the OSA approval only belongs to one of them.
What to do if you suspect sleep apnea
If the symptoms in the second section sounded familiar, here is a simple four-step framework to bring to your next appointment. Nothing here replaces a licensed clinician's evaluation — it is a starting map so you do not walk in cold.
- Ask your primary care clinician for a sleep evaluation referral. Bring a written list of symptoms — insomnia, morning headaches, fatigue, snoring if present, night-time reflux, mood changes — and how long each has been going on. A sleep specialist or sleep medicine clinic is the standard destination. If you do not have a primary care clinician, a telemedicine visit can start the referral.
- Ask about home sleep testing. Home sleep apnea tests are now widely used for adults with a moderate-to-high pre-test probability of OSA and are covered by most insurers. They are less intrusive than an in-lab study and often faster to schedule. Not everyone is a candidate — patients with certain cardiopulmonary conditions still need in-lab testing — but ask.
- If diagnosed, discuss all treatment options. Treatment for obstructive sleep apnea is not just CPAP anymore. Depending on severity and anatomy, the conversation may include positional therapy, oral appliances from a dental sleep specialist, weight-directed medical therapy such as tirzepatide for adults with obesity, and in specific cases surgical evaluation. Every option has trade-offs. Have them all on the table with your sleep clinician.
- Bring both the diagnosis and the goal to your GLP-1 conversation. If a licensed clinician is considering a GLP-1 for you, share your OSA diagnosis and your sleep-study report. It is directly relevant to clinical decision-making and, separately, to any insurance appeal you may need to file.
How SkinnyVIP handles patients with sleep apnea
SkinnyVIP is a telemedicine practice, and we offer telemedicine via a nationwide telemedicine platform. When a patient with a documented obstructive sleep apnea diagnosis begins the intake process, that history is part of the clinical picture a licensed clinician reviews — alongside weight history, medication history, labs where relevant, and any other comorbid conditions. The presence of a comorbidity like OSA is one factor a clinician weighs when determining clinical appropriateness. It is not a shortcut, and it does not guarantee a prescription. Prescription is not guaranteed.
The compounded tirzepatide program overview walks through what the clinical pathway looks like, and current pricing is on the SkinnyVIP pricing page. If you have questions about how a sleep apnea diagnosis fits into an intake — or you just want to talk to a human before starting — the contact page is the fastest route. Compounded medications are prepared by licensed compounding pharmacies under physician supervision. Compounded medications are not FDA-approved products. Individual results vary.
A closing note: this article is educational and not medical advice; talk to your clinician about diagnosis and treatment. Sleep apnea is a clinical condition with real cardiovascular and cognitive stakes, and it deserves an actual evaluation. If nothing else, take that from the trial data — even a treatment as significant as the one SURMOUNT-OSA tested still starts with a proper diagnosis.